Aromatic l‐amino acid decarboxylase (AAAD) activity in rhesus macaque striatum after MAO‐B inhibition by Ro 16‐6491

O. DeJesus,L. Flores,A. D. Roberts,D. Dick,R. Bartlett,D. Murali,R. Nickles
DOI: https://doi.org/10.1002/syn.20119
2005-04-01
Synapse
Abstract:The aromatic L-amino acid decarboxylase (AAAD) (EC 4.1.1.28) enzyme converts L-DOPA to dopamine and is critical in dopamine replacement therapy in Parkinson’s disease (PD). Following stimulated release, the action of synaptic dopamine is terminated by neuronal reuptake and deamination by monoamine oxidase (MAO). While MAO inhibition is known to downregulate tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis (Lamensdorf and Fin-berg, 1997), the effect of MAO inhibition on AAAD is unclear. There are two MAO subtypes based on substrate and inhibitor specificity, MAO-A and MAO-B (Kinemuchi et al., 1984). Dopamine is effectively de-aminated by both subtypes, but MAO-B has higher activity than MAO-A in the primate striatum, suggesting that MAO-B plays a greater role than MAO-A in striatal dopamine metabolism in primates (Paterson et al., 1995). By slowing dopamine degradation and maximizing L-DOPA efficacy, MAO-B inhibitors may be useful in PD therapy, as suggested by Napolitano et al. (1995). Earlier nonhuman primate studies on the effect of MAO-B inhibition on AAAD activity involved the use of L-deprenyl (
What problem does this paper attempt to address?